Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769389 | 0.84 | MAPT (0.39) | POLBNPSR1MAPTSMN1; SMN2GRM5 | |
| SCHEMBL2770063 | 0.82 | GSR (0.38) | PPARGPOLBTRPM2MAPTSMN1; SMN2 | |
| SCHEMBL2774909 | 0.77 | KDM4E (0.40) | NPSR1MAPTSMN1; SMN2GRM5HPGD | |
| SCHEMBL23639734 | 0.73 | MCHR1 (0.47) | POLBMAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL2772073 | 0.71 | GAA (0.42) | AKR1C3NPSR1MAPTSMN1; SMN2GAA | |
| SCHEMBL1045007 | 0.71 | MAPT (0.56) | PPARGPOLBNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL24651096 | 0.70 | POLB (0.45) | PPARGPOLBNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL23218135 | 0.69 | ANO1 (0.45) | POLBNPSR1MAPTGAAL3MBTL1 | |
| SCHEMBL29852434 | 0.69 | ANO1 (0.45) | POLBNPSR1MAPTGAAL3MBTL1 | |
| SCHEMBL513210 | 0.69 | IDO1 (0.48) | POLBNPSR1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910357-B1 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LTD (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| CN-101243086-A | Indolizine derivatives and their use as CRTH2 antagonists | ARGENTA DISCOVERY LTD (GB) | 2008-08-13 | — | — | CN | disclosed |
| EP-1910357-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006136859-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163534-A1 | Indolizine Derivatives | HRH4, HRH2, NR1H2 | PPARG 1671/4885POLB 4250/4885TRPM2 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.